Portfolio

 

 

Xilis


 
MediumSquareLogo.jpg
 
 

“Xilis is developing a rapid and scalable patient-derived miniature-organoid technology platform to revolutionize precision medicine and pharmaceutical drug discovery. Our micro-organospheres lead to 30x speed, 50x throughput, and 300x cost savings compared to organoids. They remove barriers to conventional organoids going from predictive, accurate research tools to actual clinical practice, and provide unequaled potential for large-scale pharmacogenomic studies representative of the breadth of human genetic diversity during pre-clinical development.”

  • Founders: Xiling Shen, David Hsu, & Hans Clevers

  • Location: Raleigh / Durham, North Carolina

  • Category: Life Sciences / Diagnostics / Oncology

  • Company Stage: Series A

  • Co-Investors: Mubadala, LSP, GV, Felicis, 8VC, Two Sigma, amongst others

 
 

Team


 
Screen Shot 2020-07-26 at 12.00.41 AM.png
 

Media


 
 

Founder Spotlight

 

Market Research

 
 
 

Fierce Feature

 

BIOS Podcast

 
 
 

Biospace List - 2022